Filing Flows › Corcept Therapeutics (CORT) › Q3 2026 › vs Q2 2026
Corcept Therapeutics (CORT) Q3 2026 vs Q2 2026 (quarter over quarter)
Corcept Therapeutics's revenue rose $84.3M (+33%) from $256M in Q2 2026 to $340M in Q3 2026. The biggest changes: Lifyorli +$43.8M (+92%); Hypercortisolism Products +$40.5M (+19%). Operating margin 33.7% against 16.1% (+17.6 pts).
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 33.7% | 16.1% | +17.6 pts |
| Net margin | 37.2% | 16.8% | +20.5 pts |
| Free cash flow margin | 41.8% | 12.1% | +29.7 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Hypercortisolism Products | $249M | $209M | $40.5M | +19% |
| Lifyorli | $91.4M | $47.6M | $43.8M | +92% |
| Revenue | $340M | $256M | $84.3M | +33% |
| Other income, net | $5.6M | $4.6M | $952K | +21% |
| Operating profit | $115M | $41.3M | $73.4M | +178% |
| Costs & expenses | $226M | $215M | $10.9M | +5% |
| Pre-tax earnings | $120M | $45.9M | $74.4M | +162% |
| Cost of revenue | $4.6M | $4.1M | $547K | +13% |
| Research & development | $56.7M | $53.9M | $2.8M | +5% |
| SG&A | $164M | $157M | $7.5M | +5% |
| Income tax benefit | $6.5M | −$2.9M | $9.4M | — |
| Net earnings | $127M | $43.0M | $83.8M | +195% |
| Depreciation & amortization | $1.0M | $863K | $163K | +19% |
| Share-based compensation | $29.4M | $29.4M | $27K | +0.1% |
| Working capital & other | $14.4M | $39.7M | −$25.4M | -64% |
| Operating cash flow | $143M | $33.5M | $109M | +326% |
| Free cash flow (OCF − capex) | $142M | $31.0M | $111M | +358% |
| Capital expenditures | $709K | $2.5M | −$1.8M | -72% |
Questions
How much did Corcept Therapeutics's revenue grow quarter over quarter in Q3 2026?
Corcept Therapeutics's revenue rose $84.3M (+33%) from $256M in Q2 2026 to $340M in Q3 2026.
What drove Corcept Therapeutics's revenue change in Q3 2026?
Lifyorli +$43.8M (+92%); Hypercortisolism Products +$40.5M (+19%).